Hengrui Pharma(SH:600276) Mei Ri Jing Ji Xin Wen·2025-07-29 02:07Group 1 - The A-share market saw all three major indices rise on July 28, with the Shanghai Composite Index up 0.12%, the Shenzhen Component Index up 0.44%, and the ChiNext Index up 0.96% [1] - The A500 ETF (512050), which tracks the CSI A500 Index, experienced a strong increase of 0.49%, with a trading volume exceeding 4 billion yuan, maintaining the top position among similar funds for several consecutive trading days [1][2] - Key stocks within the A500 ETF, such as Shenghong Technology, surged over 17%, while several other holdings like Heng Rui Pharmaceutical and Xing Sen Technology hit the daily limit [1] Group 2 - Heng Rui Pharmaceutical announced a potential license-out collaboration with GlaxoSmithKline (GSK) worth up to 12.5 billion USD, covering an innovative respiratory drug in clinical stages and up to 11 candidates in non-clinical stages [1] - The global pharmaceutical transaction volume is projected to reach 456 deals in the first half of 2025, a 32% year-on-year increase, with total upfront payments amounting to 11.8 billion USD, a 136% surge, and total transaction value hitting 130.4 billion USD, up 58% year-on-year [1] - Transactions involving China contributed nearly 50% of the total transaction value and over 30% of the total number of deals globally [1]